2004
DOI: 10.1097/00042728-200405000-00029
|View full text |Cite
|
Sign up to set email alerts
|

Radiance FN

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2008
2008
2010
2010

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 6 publications
0
2
0
Order By: Relevance
“…Radiesse was recently approved in the United States for facial cosmetic applications, such as correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, and restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV). Radiesse has also been used off‐label in the United States for a variety of aesthetic applications, including nasal augmentation and contouring, cheek augmentation and rejuvenation, correction of marionette lines, and correction of depressed scars 4,5–10 …”
Section: Radiessementioning
confidence: 99%
“…Radiesse was recently approved in the United States for facial cosmetic applications, such as correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, and restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus (HIV). Radiesse has also been used off‐label in the United States for a variety of aesthetic applications, including nasal augmentation and contouring, cheek augmentation and rejuvenation, correction of marionette lines, and correction of depressed scars 4,5–10 …”
Section: Radiessementioning
confidence: 99%
“…The dermal filler calcium hydroxylapatite (CaHA; Radiesse Dermal Filler (RDF), BioForm Medical Inc, San Mateo, CA) is a synthetic material approved by the Food and Drug Administration (FDA) in late 2006 for treating facial lines and wrinkles such as nasolabial folds (NLFs) 1 . CaHA has been used since 2002 with an excellent safety and side‐effect profile for patients with human immunodeficiency virus–associated lipoatrophy and for reducing facial wrinkles and correction of the NLFs 2–4 . The FDA has also approved CaHA for a variety of indications such as radiographic tissue marking, vocal cord insufficiency, oral and maxillofacial augmentation, correction of NLF wrinkles, and urinary incontinence.…”
mentioning
confidence: 99%